Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Jetema Co., Ltd. (216080:KRX), powered by AI.
Jetema Co., Ltd. is currently trading at ₩7,380. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Jetema Co., Ltd. on Alpha Lenz.
Jetema Co., Ltd.'s P/E ratio is -2801.4.
“Jetema Co., Ltd. trades at a P/E of -2801.4 (undervalued) with modest ROE of -0.3%. 3Y revenue CAGR of 27.3% highlights clear growth momentum.”
Ask for details →Jetema Co., Ltd., a South Korean company, is primarily engaged in the biotechnology sector, focusing on developing, manufacturing, and marketing medical aesthetics and pharmaceuticals. The firm's core products include botulinum toxin, commonly used in non-surgical cosmetic procedures, and hyaluronic acid fillers, designed for skin rejuvenation and anti-aging treatments. Jetema Co., Ltd. also engages in the production of microneedles aimed at drug delivery applications, showcasing its commitment to innovative medical technologies. The company serves a variety of markets, impacting not only the beauty and cosmetics industry but also the pharmaceutical sector through its research-driven approach. By leveraging advanced biotechnology, Jetema Co., Ltd. aims to provide effective solutions for both aesthetic enhancements and therapeutic treatments. In the financial market, Jetema Co., Ltd. represents an entity focused on combining scientific research with consumer demand for beauty and health products. It plays a significant role in the cosmetic procedures market, which is experiencing growth due to increasing consumer interest in anti-aging solutions and non-invasive medical treatments globally.
“Jetema Co., Ltd. trades at a P/E of -2801.4 (undervalued) with modest ROE of -0.3%. 3Y revenue CAGR of 27.3% highlights clear growth momentum.”
Ask for details →Jetema Co., Ltd. (ticker: 216080) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). It has approximately 235 employees. Market cap is $264.6B.
The current price is ₩7,380 with a P/E ratio of -2,801.44x and P/B of 7.3x.
ROE is -0.26% and operating margin is 6.00%. Annual revenue is $68.5B.